ClinicalTrials.gg
CompletedNCT00000971Updated Aug 4, 2008

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

A Phase 1 interventional study of Clarithromycin and Zidovudine in Mycobacterium Avium-intracellulare Infection and HIV Infections, sponsored by Abbott. Completed at 2 sites in United States. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2008-08-04.

Sponsored by Abbott · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Ages
3 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Mycobacterium avium-intracellulare Infection · United States.

Enrollment
30th of 37
24 · median 100
Phase 1
7 of 52
1 open now
Registered
1st of 52
by date
Lead sponsor
1 of 52
Abbott

Among the 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States, this one is the 30th largest by enrollment of the 37 interventional ones that give a count, is one of 7 in phase 1, and was the 1st registered.

Mycobacterium avium-intracellulare Infection

66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.

Browse Mycobacterium avium-intracellulare Infection studies →

Open to participants now

3 of the 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Mycobacterium avium-intracellulare Infection studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 3 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States, or all of them as a file.
02

Study summary

To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy.

Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.

Read the detailed description

Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.

Patients that are included are HIV infected and have started zidovudine (AZT) or didanosine (ddI) at least 4 weeks before entry into this study. Patients continue taking the medications at prescribed doses. In addition they also take clarithromycin. Patients continue treatment with AZT or ddI plus clarithromycin for 12 weeks.

03

Conditions studied

  • Mycobacterium Avium-intracellulare Infection
  • HIV Infections

Keywords

  • AIDS-Related Opportunistic Infections
  • Mycobacterium avium-intracellulare Infection
  • Didanosine
  • Drug Evaluation
  • Drug Interactions
  • Drug Therapy, Combination
  • Acquired Immunodeficiency Syndrome
  • Zidovudine
04

Who can participate

Ages eligible
3 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Prophylaxis treatment for Pneumocystis carinii pneumonia.
  • Topical antivirals.

Prior Medication: Required:

  • Zidovudine (AZT), 90 - 180 mg/m2 q6h, or didanosine (ddI), 60 - 120 mg/m2 q8h for 4 weeks prior to study entry.

Patients must have the following:

  • Diagnosis of AIDS and Mycobacterium avium complex.
  • Ability to tolerate therapy with zidovudine or didanosine at specified dosages.
  • Written consent from a parent or legal guardian.
  • Willing to comply with all procedures and scheduled visits. Relatively stable clinical condition.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • History of significant depressive disorder.
  • History of allergy to macrolide antibiotics.
  • Presence of acute bacterial infection or acute onset of opportunistic infection as listed in protocol.

Patients with the following are excluded:

  • Presence of current opportunistic infection other than Mycobacterium avium complex defined as systemic candidemia, cryptosporidiosis, isosporiasis, toxoplasmosis, pneumocystosis, salmonellosis, or acute bacterial infection.

Prior Medication:

Excluded within 30 days of study entry:

  • Systemic antimycobacterial drugs, myelosuppressive drugs, nephrotoxic agents, cytotoxic or experimental chemotherapy, or antiviral drugs.

Active alcohol or drug use sufficient in the opinion of the investigator to prevent adequate compliance with medication regimen and clinic visits.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Enrollment
24 participants

Interventions

06

Study locations

2 sites
  • Children's Hosp of Los Angeles
    Los Angeles, California 90027, United States
  • Natl Cancer Institute / HIV / AIDS Malignancy Branch
    Bethesda, Maryland 20892, United States
07

References and documents

Publications

  • Husson RN, Ross LA, Sandelli S, Inderlied CB, Venzon D, Lewis LL, Woods L, Conville PS, Witebsky FG, Pizzo PA. Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. J Pediatr. 1994 May;124(5 Pt 1):807-14. doi: 10.1016/s0022-3476(05)81380-0. PubMed 8176574 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00000971
Lead sponsor
Abbott
First posted
Aug 31, 2001
Last update
Aug 4, 2008

Study contacts

Pizzo P
study chair
Husson R
study chair
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clarithromycin · Zidovudine

Start the discussion